FDA approval for MiniMed 780G system the World's first insulin pump with meal detection technology featuring 5-Minute auto corrections.-Medtronic

This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes for both basal (background) and bolus (mealtime) insulin needs. The system provides insulin to help account for when users occasionally forget to bolus or underestimates the number of carbs in their meal.

"Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes and now for the first time, the MiniMed 780G system addresses this unmet need with automatic, real-time insulin corrections," said Que Dallara, EVP and President of Medtronic Diabetes. "A lot can happen to blood sugars in the span of an hour or even just a few minutes, so we've designed our system for real life – the algorithm adapts to the user and helps compensate for everyday challenges that are quite common around mealtimes. We built in features informed by extensive customer feedback and we're excited to deliver a system with ease of use at the forefront."

Key System Features: The MiniMed 780G system features the lowest glucose target setting (as low as 100 mg/dL) in any automated insulin pump on the market and one that more closely mirrors the average glucose of someone not living with diabetes. With this setting, the pump will "treat to target" and will automatically deliver basal insulin adjustments and autocorrections to a set target. It is also the only pump with an infusion set that can be worn for up to 7 days, doubling wear time with advanced materials that help reduce insulin preservative loss, maintain insulin flow and stability, resulting in a reduced risk of infusion set occlusion. Current infusion sets are recommended for up to 3 days of wear. Combined with the new Guardian 4 sensor requiring no fingersticks with SmartGuard technology, the MiniMed 780G system delivers a user-friendly design with 94% of users saying they're satisfied with the impact the system has on their quality of life. Importantly, users also reported remaining in SmartGuard technology 95% of the time.

The system is approved for users seven years old and above with type 1 diabetes. Medtronic will begin taking pre-orders on May 15, 2023, with first shipments planned for later this summer. Customers on the company's MiniMed 770G systemy will be eligible to upgrade their device to the MiniMed 780G through a no-cost, remote software upgrade.

Results from the randomized controlled ADAPT study evaluating the performance of the MiniMed 780G system against multiple daily injections (MDI) used in conjunction with an intermittently scanned CGM (isCGM) reinforced the significant benefits of automated insulin therapy over standard therapy. Initial 6-month results, published in The Lancet Diabetes & Endocrinology, showed AHCL system users experienced a 27.6% increase in Time in Range (TIR) and 1.4% reduction in HbA1C compared to those on MDI + isCGM without increased time in hypoglycemia. This improvement was even greater overnight with a TIR increase of 30.2%. At the close of the 6-month study period, all participants on MDI + isCGM crossed over to the MiniMed 780G system. At one year, these significant improvements were reproduced in this cross-over group and sustained in those that started on AHCL therapy at the start of the trial.

See- "Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study." Prof Pratik Choudhary, MBBS, Ralf Kolassa, MD, Winfried Keuthage, MD , Jens Kroeger, MD, Prof Charles Thivolet, MD, Prof Mark Evans, MD ,et al. Published:September 01, 2022DOI:https://doi.org/10.1016/S2213-8587(22)00212-1.